Opinion
Video
CDK4/6 Inhibitors for HR+/HER2- Early Breast Cancer
Panelists discuss how adjuvant therapy in HR+/HER2- early-stage breast cancer is influenced by key risk factors, with a focus on recent studies involving CDK4/6 inhibitors like abemaciclib, ribociclib, and palbociclib, and how these treatments are shaping the adjuvant treatment strategy based on efficacy data from trials such as MonarchE, NATALEE, and PALLAS.
Video content above is prompted by the following:
- How do you use adjuvant therapy in patients with HR+/HER2- early-stage breast cancer (eBC)?
- How do risk factors impact your adjuvant treatment strategy?
- Which risk factors are most influential, and why?
- Please briefly mention adjuvant CDK4/6i studies in eBC
Related Videos
Related Content
